Effectiveness and safety of Sofosbuvir and Daclatasvir in Treatment-Naïve non-Cirrhotic Hepatitis C Patients. A Prospective Study
Proceedings · 08.07.2026 · 40 (2) · 214-221
DOI: 10.47489/szmc.v40i2.948 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings, online erschienen am 08.07.2026. Verfasst von Umair Ahmad und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hepatitis C virus (HCV) infection remains a major global health concern, particularly in South Asia, where genotype 3 is most common. When compared to interferon therapy, the introduction of direct-acting antivirals (DAAs), such as sofosbuvir and daclatasvir, has resulted in significantly higher cure rates and fewer or no side effects.
Objective
This research aimed to evaluate the safety and effectiveness of the sofosbuvir–daclatasvir combination in non-cirrhotic, treatment-naïve individuals with chronic HCV infection.
Methods
This prospective observational research was conducted from May to November 2025 at the medical outpatient department of Allied Hospital in Faisalabad. Convenience sampling was used to select 85 HCV RNA-positive individuals (20–60 years old) without cirrhosis. Daclatasvir (60 mg) and sofosbuvir (400 mg) were administered daily for 12 weeks to each patient. The effectiveness of the therapy was assessed using the sustained virological response at 12 weeks following the conclusion of treatment (SVR-12). Data analysis was done using SPSS version 23. For quantitative data, mean ± standard deviation was employed, whereas for qualitative variables, frequencies and percentages were used. Associations were evaluated using the chi-square test, with p < 0.05 being deemed statistically significant.
Results
The respondents were 63.5% male and 36.5% female, with an average age of 45.2 ± 8.1 years. The average BMI was 29.4 ± 3.5 kg/m². 82.4% (n = 70) of patients attained SVR-12 at 12 weeks after therapy, but 17.6% (n = 15) were still HCV RNA positive. Age, gender, BMI, and baseline viral load did not significantly correlate with treatment response (p>0.05). Fatigue (27.0%), headache (18.9%), and nausea (16.5%) were the most often reported side effects, the majority of which were minor. No significant adverse effects were observed.
Conclusion
The combination of sofosbuvir and daclatasvir is an effective and well-tolerated treatment option for treatment-naïve, non-cirrhotic patients with chronic hepatitis C, supporting its continued use in routine clinical practice, particularly in resource-limited settings.
Zitieren
APA
Ahmad, U., Ahmed, B., Khan, S. A., Shaukat, A., Ahmad, A., & Murtaza, H. B. (2026). Effectiveness and safety of Sofosbuvir and Daclatasvir in Treatment-Naïve non-Cirrhotic Hepatitis C Patients. A Prospective Study. Proceedings, 40(2), 214-221. https://doi.org/10.47489/szmc.v40i2.948
Vancouver
Ahmad U, Ahmed B, Khan SA, Shaukat A, Ahmad A, Murtaza HB. Effectiveness and safety of Sofosbuvir and Daclatasvir in Treatment-Naïve non-Cirrhotic Hepatitis C Patients. A Prospective Study. Proceedings. 2026;40(2):214-221. doi:10.47489/szmc.v40i2.948
BibTeX
@article{Ahmad2026,
author = {Ahmad, Umair and Ahmed, Bilal and Khan, Shahzad Alam and Shaukat, Aamir and Ahmad, Awais and Murtaza, Hafiz Bilal},
title = {Effectiveness and safety of Sofosbuvir and Daclatasvir in Treatment-Naïve non-Cirrhotic Hepatitis C Patients. A Prospective Study},
journal = {Proceedings},
year = {2026},
volume = {40},
number = {2},
pages = {214--221},
doi = {10.47489/szmc.v40i2.948}
}
EUVIMED